Empagliflozin (JARDIANCE®) is proven to go beyond lowering A1C to reduce the risk of CV death for adults who have type 2 diabetes and heart disease
HF Video Prof. Melanie Davies - Jardiance safety for HF patients with T2D
31/01/2025 | Author: Boehringer Ingelheim
Document ID: PC-PH-106226